Novo Nordisk's Wegovy wins EU backing for reducing heart risks
Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults.